Truncated p53 proteins, presumed unimportant, now point to new drug targets for some of ‘the hardest cancers,’ report scientists in a new report.
Truncated p53 proteins, presumed unimportant, now point to new drug targets for some of ‘the hardest cancers,’ report scientists in a new report.